Low efficacy and high price of dapivirine ring: not included as PrEP in South African guidelines

27 July 2024. Related: Guidelines, HIV prevention and transmission.

Simon Collins, HIV i-Base

A systematic search for high-quality up-to-date evidence has failed to support recommending dapivirine ring as PrEP in South African public health guidelines.

Although comparative data is limited the review commented that dapivirine appears less effective than oral PrEP and doesn’t cover use in adolescents or during pregnancy.

The review also included a cost-effectiveness analysis but reported that dapivirine is less cost-effective than oral PrEP at the current price of $14.59/ring.

The review is published in the July issue of the journal JAIDS.

Reference